The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction

被引:0
|
作者
Álvaro Quintanal-Villalonga
Laura Ojeda-Márquez
Ángela Marrugal
Patricia Yagüe
Santiago Ponce-Aix
Ana Salinas
Amancio Carnero
Irene Ferrer
Sonia Molina-Pinelo
Luis Paz-Ares
机构
[1] Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO),Medical Oncology Department
[2] Universidad de Sevilla),Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC
[3] Universidad Complutense,Medical School
[4] CIBER de Cáncer,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung cancer. The mechanism underlying this association has not been addressed in detail in patients with this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes pro-oncogenic effects in NSCLC in vitro and in vivo. This variant induces the expression of EMT-related genes, such as N-cadherin, vimentin, Snail1 and Twist1. Indeed, the induction of N-cadherin protein expression by this variant is essential for its pro-tumorigenic role. The presence of the FGFR4-388Arg variant correlates with higher N-cadherin expression levels in clinical NSCLC samples and with poorer outcome in patients with FGFR expression. These results support the prognostic role of this FGFR variant in lung cancer and show that these effects may be mediated by the induction of N-cadherin expression and an EMT phenotype.
引用
收藏
相关论文
共 50 条
  • [31] N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties
    Qian, X.
    Anzovino, A.
    Kim, S.
    Suyama, K.
    Yao, J.
    Hulit, J.
    Agiostratidou, G.
    Chandiramani, N.
    McDaid, H. M.
    Nagi, C.
    Cohen, H. W.
    Phillips, G. R.
    Norton, L.
    Hazan, R. B.
    ONCOGENE, 2014, 33 (26) : 3411 - 3421
  • [32] FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
    Xu, Bin
    Tong, Na
    Chen, Shu Q.
    Hua, Li X.
    Wang, Zeng J.
    Zhang, Zheng D.
    Chen, Ming
    BMC CANCER, 2011, 11
  • [33] FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
    Bin Xu
    Na Tong
    Shu Q Chen
    Li X Hua
    Zeng J Wang
    Zheng D Zhang
    Ming Chen
    BMC Cancer, 11
  • [34] FGFR-4 Arg388 Enhances Prostate Cancer Progression via Extracellular Signal-Related Kinase and Serum Response Factor Signaling
    Yu, Wendong
    Feng, Shu
    Dakhova, Olga
    Creighton, Chad J.
    Cai, Yi
    Wang, Jianghua
    Li, Rile
    Frolov, Anna
    Ayala, Gustavo
    Ittmann, Michael
    CLINICAL CANCER RESEARCH, 2011, 17 (13) : 4355 - 4366
  • [35] N-cadherin promotes adhesion between invasive breast cancer cell lines and the stroma.
    Hazan, RB
    Kang, L
    Whooley, BP
    Borgen, PI
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 2450 - 2450
  • [36] Fibroblast growth factor receptor 4 (FGFR4) variant p. Gly388Arg in Czech children carcinoma patients
    Valaskova, I.
    Drabova, K.
    Spesna, R.
    Gaillyova, R.
    Sterba, J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1899 - 1899
  • [37] FGFR4 Arg388 polymorphism is a poor prognostic factor for resected stage III colon cancer
    Cho, Sang-Hee
    Shin, Min-Ho
    Kweon, Sun-Seog
    Kim, Hee-Nam
    Shim, Hyun-Jeong
    Hwang, Jun-Eul
    Bae, Woo-Kyun
    Chung, Lk-Joo
    CANCER RESEARCH, 2015, 75
  • [38] Polymorphism of FGFR4 Gly388Arg Does Not Confer an Increased Risk to Breast Cancer Development
    Naidu, R.
    Har, Y. C.
    Taib, N. A.
    ONCOLOGY RESEARCH, 2009, 18 (2-3) : 65 - 71
  • [39] FGFR4Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
    Cho, Sang Hee
    Hong, Chang Soo
    Kim, Hee Nam
    Shin, Min Ho
    Kim, Ka Rham
    Shim, Hyun Jeong
    Hwang, Jun Eul
    Bae, Woo Kyun
    Chung, Ik Joo
    CANCER RESEARCH AND TREATMENT, 2017, 49 (03): : 766 - 777
  • [40] FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas, C.
    Nahrig, J.
    Streit, S.
    Bange, J.
    Kates, R.
    Ulm, K.
    Kiechle, M.
    Hoefler, H.
    Ullrich, A.
    Harbeck, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 34S - 34S